Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Bristol-Myers Squibb Co (BMY)  
$53.25 0.70 (1.33%) as of 4:30 Wed 3/27


Download
   
Exchange: New York Stock Exchange
Security Type: Common
Shares Out: 2,250,000,000
Market Cap: 119.81(B)
Last Volume: 13,077,368 Avg Vol: 11,927,860
52 Week Range: $47.98 - $70.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Major

Member Indexes:

    S&P COMPOSITE 1500     NYSE COMPOSITE
    S&P 100     S&P 500

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    : 11.3
Insider 3/6 Months : 11.9
Guru Rank Number :  97
Guru Rank Value     : 8.6
Guru Occurances    : 3

 

            6 Months   1 Year   2 Year  
 
Company Profile   Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 13,571 13,571 13,571
Total Buy Value $0 $672,994 $672,994 $672,994
Total People Bought 0 2 2 2
Total Buy Transactions 0 3 3 3
Total Shares Sold 0 0 69,103 681,397
Total Sell Value $0 $0 $4,525,215 $49,727,684
Total People Sold 0 0 3 6
Total Sell Transactions 0 0 3 12
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 2223
  Page 1 of 89  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Leung Sandra EVP, General Counsel   •       –      –    2024-03-10 4 D $53.79 $896,141 D/D (16,660) 347,385     -
   Leung Sandra EVP, General Counsel   •       –      –    2024-03-10 4 D $0.00 $0 D/D (14,153) 359,080     -
   Leung Sandra EVP, General Counsel   •       –      –    2024-03-10 4 OE $0.00 $0 D/D 46,784 371,312     -
   Gallman Cari EVP, Corporate Affairs   •       –      –    2024-03-10 4 D $53.79 $37,438 D/D (696) 1,432     -
   Gallman Cari EVP, Corporate Affairs   •       –      –    2024-03-10 4 D $0.00 $0 D/D (839) 1,926     -
   Gallman Cari EVP, Corporate Affairs   •       –      –    2024-03-10 4 OE $0.00 $0 D/D 2,761 2,655     -
   Boerner Christopher S. Chief Executive Officer   •       •      –    2024-03-10 4 D $53.79 $1,043,903 D/D (19,407) 101,205     -
   Boerner Christopher S. Chief Executive Officer   •       •      –    2024-03-10 4 D $0.00 $0 D/D (16,698) 115,180     -
   Boerner Christopher S. Chief Executive Officer   •       •      –    2024-03-10 4 OE $0.00 $0 D/D 54,638 129,769     -
   Elkins David V EVP, Chief Financial Officer   •       –      –    2024-03-10 4 D $53.79 $996,298 D/D (18,522) 194,968     -
   Elkins David V EVP, Chief Financial Officer   •       –      –    2024-03-10 4 D $0.00 $0 D/D (19,448) 208,313     -
   Elkins David V EVP, Chief Financial Officer   •       –      –    2024-03-10 4 OE $0.00 $0 D/D 64,326 225,111     -
   Hoch Lynelle President, Cell Therapy Org.   •       –      –    2024-03-10 4 D $53.79 $70,357 D/D (1,308) 1,726     -
   Hoch Lynelle President, Cell Therapy Org.   •       –      –    2024-03-10 4 D $0.00 $0 D/D (1,317) 2,643     -
   Hoch Lynelle President, Cell Therapy Org.   •       –      –    2024-03-10 4 OE $0.00 $0 D/D 4,351 3,781     -
   Holzer Phil M SVP and Controller   •       –      –    2024-03-10 4 D $53.79 $74,714 D/D (1,389) 12,460     -
   Holzer Phil M SVP and Controller   •       –      –    2024-03-10 4 D $0.00 $0 D/D (1,682) 13,452     -
   Holzer Phil M SVP and Controller   •       –      –    2024-03-10 4 OE $0.00 $0 D/D 5,520 14,916     -
   Caforio Giovanni Executive Chair of the Board   •       •      –    2024-03-10 4 D $53.79 $3,648,199 D/D (67,823) 432,266     -
   Caforio Giovanni Executive Chair of the Board   •       •      –    2024-03-10 4 D $0.00 $0 D/D (57,536) 479,917     -
   Caforio Giovanni Executive Chair of the Board   •       •      –    2024-03-10 4 OE $0.00 $0 D/D 190,130 529,662     -
   Plenge Robert M EVP, Chief Research Officer   •       –      –    2024-03-10 4 D $53.79 $105,697 D/D (1,965) 11,315     -
   Plenge Robert M EVP, Chief Research Officer   •       –      –    2024-03-10 4 D $0.00 $0 D/D (2,789) 12,751     -
   Plenge Robert M EVP, Chief Research Officer   •       –      –    2024-03-10 4 OE $0.00 $0 D/D 9,143 15,182     -
   Lenkowsky Adam EVP, Chief Commercial Officer   •       –      –    2024-03-10 4 D $53.79 $232,534 D/D (4,323) 6,650     -

  2223 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 89
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed